Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Maureen Cooper

Hematology & Oncology Alamosa, CO Medical Doctor

NPI 1356310890 CMS profile 151662

2115 Stuart Ave, Alamosa, CO 81101

Open in the dashboard

General payments

$84,977

217 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$5,450 paid to institutions, not to them · program years 2021–2023

Through program year 2023, Maureen Cooper of Alamosa, CO is reported in the CMS Open Payments database as having received $84,977 across 217 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $5,450 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 92nd percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $12,292 23
2022 General $12,014 52
2021 General $13,381 55
2020 General $5,765 19
2019 General $41,525 68

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Maureen Cooper
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to Maureen Cooper were reported at $0. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year Maureen Cooper Hematology & Oncology median Middle half National median
2019 $41,525 $529 $121–$2,516 $163
2020 $5,765 $339 $82–$2,213 $114
2021 $13,381 $263 $49–$1,965 $132
2022 $12,014 $416 $103–$2,395 $149
2023 $12,292 $542 $125–$2,646 $160
2024 $0 $692 $141–$3,008 $164
2025 $0 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Amgen Inc. $65,862 104 payments
  2. Janssen Biotech, Inc. $5,033 15 payments
  3. Incyte Corporation $4,638 10 payments
  4. GlaxoSmithKline, LLC. $2,390 4 payments
  5. Array BioPharma Inc. $1,902 2 payments
  6. Novartis Pharmaceuticals Corporation $1,779 37 payments
  7. Jazz Pharmaceuticals Inc. $1,532 3 payments
  8. Genentech USA, Inc. $999 3 payments
  9. Daiichi Sankyo Inc. $160 3 payments
  10. Janssen Scientific Affairs, LLC $103 2 payments
  11. Other $579 34 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $50,390 28 payments
  2. Travel and Lodging $18,140 55 payments
  3. Consulting Fee $11,530 8 payments
  4. Food and Beverage $3,204 100 payments
  5. Long term medical supply or device loan $1,515 17 payments
  6. Education $173 8 payments
  7. Gift $25 1 payment
Products named General payments · program years 2019–2023
  1. Nplate $65,712 95 payments
  2. IMBRUVICA $4,930 12 payments
  3. BRAFTOVI $1,902 2 payments
  4. BLENREP $1,840 1 payment
  5. VYXEOS $1,519 2 payments
  6. KISQALI $1,480 26 payments
  7. Perjeta $975 2 payments
  8. Kadcyla $910 1 payment
  9. Herceptin $910 1 payment
  10. ZEJULA $425 1 payment
  11. Other $1,751 96 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

217 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology & Oncology in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record